Sclerotherapy of liver hemangioma

Percutanous sclerotherapy of symptomatic liver hemangioma with Bleomycin, a pilot study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016021626599N1

Enrollment

Registered

2016-03-31

Start date

2016-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver symptomatic hemangioma. Haemangioma, any site

Interventions

Intervention group: Under local anesthectic and ultrasound guidance, needle is advanced into the liver hemangioma.Under flurouscopy contrast agent (Lipiodol) is injected to rule out communication of t

Treatment - Other

Intervention group: Under local anesthectic and ultrasound guidance, needle is advanced into the liver hemangioma.Under flurouscopy contrast agent (Lipiodol) is injected to rule out communication of

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with symptomatic liver hemangioma with therapeutic indication with confirmed diagnosis based on triphasic CT-scan or dynamic MRI. Exclusion criteria: Those patients that their abdominal complaints could be attributed to another cause, apart from liver hemangioma

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Abdominal pain. Timepoint: one month and 6 month after procedure. Method of measurement: visual analog scale.	—

Primary

Measure	Time frame
Volume of lesion. Timepoint: 6 month after therapy. Method of measurement: Digital volumetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Rokni Yazdi

Tehran university of Medical Sciences

rokniyaz@tums.ac.ir+98 21 6658 1536

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026